United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

29 Sep 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MNKD.OQ


MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)


Beta: 2.29
Market Cap(Mil.): $286.02
Shares Outstanding(Mil.): 478.05
Dividend: --
Yield (%): --


  MNKD.OQ Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -0.86 -- --
ROI: -- -0.27 13.98
ROE: -- -2.93 14.88

BRIEF-Securities Class Action Against MannKind Dismissed

* U.S. District court for central district of California has dismissed class action that was pending against Mannkind and two of executives

Aug 25 2016

BRIEF-Mannkind's cco Michael Castagna reports open market purchase of 25,000 shares for $0.94 per share

* Mannkind's cco Michael Castagna reports open market purchase of 25,000 shares of co's common stock on august 23 for $0.94per share Source text - http://bit.ly/2bmQuTg Further company coverage:

Aug 24 2016

BRIEF-Mannkind Corporation reports 2016 Q2 financial results

* Mannkind Corporation reports 2016 second quarter financial results

Aug 08 2016

BRIEF-Mannkind says distributing Afrezza directly to wholesalers

* Mannkind assumes responsibility for distribution of Afrezza and launches patient reimbursement and adherence support programs Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 01 2016

BRIEF-MannKind announces pricing of public offering of common stock and warrants

* MannKind Corp says A warrants will be exercisable at a price of $1.50 per share

May 09 2016

BRIEF-Mannkind reports Q1 net loss $0.06 per share

* Net loss for Q1 of 2016 was $24.9 million, or $0.06 per share

May 09 2016

BRIEF-Mannkind entered into ATI sales agreement with FBR Capital Markets & Co - SEC filing

* Says pursuant to agreement co may sell shares having an aggregate offering price of up to $50 million from time to time through FBR

May 04 2016

BRIEF-Mannkind- regains Afrezza marketing rights

* Has assumed responsibility for worldwide development and commercialization of Afrezza inhalation powder from Sanofi

Apr 05 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.